



Ref.No. Z-IV/R-39/D-2/NSE/207 & 174

Date : 25/05/2018

National Stock Exchange of India Ltd. Listing Deptt., Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051	BSE Ltd. Regd. Office: Floor - 25, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400 001.
NSE Scrip: MINDAIND	BSE Scrip: 532539

Sub: Submission of clippings of the newspapers

Dear Sir(s),

This is in continuation of our earlier letter(s) dated 14/05/2018, 16/05/2018 and 22/05/2018.

In terms of regulation 47(1) (b) of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and as per the format prescribed in Annexure-XI to SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016, **we are pleased to inform that the audited financial results of the company for the quarter and year ended 31 March, 2018 has been got published in the newspapers on 23 May, 2018 in "Economic Times" (English) and Navbharat Times (Hindi) newspapers.** The clippings of both the newspapers are enclosed herewith for your reference and record please.

Thanking you.

Yours faithfully,
For MINDA INDUSTRIES LTD.



Tarun Kumar Srivastava
Company Secretary & Compliance Officer

Encl: As above.

पुर में दिनांक 30/05/2018 समय 5:00 बजे तक
 प्रारूप स्वराशी चिकित्सा महाविद्यालय छिंदवाड़ा
 .com" एवं www.medicaleducation.

वन), पासकीय स्वराशी नेताजी सुभाष चन्द्र बोस
 प्रारूप में भरा हुआ आवेदन पत्र, समस्त दस्तावेजों

में शैक्षणिक संवर्ग हेतु आवेदन एवं विषय.... तथा
 श्रेणी का उल्लेख अनिवार्य रूप से करें।
 विचार नहीं किया जायेगा।

जायेगा। साक्षात्कार की समय सारणी कॉलेज
 शल चिकित्सा महाविद्यालय की वेबसाइट www.

प्र. तो बाद में अन्य उम्मीदवारों को बुलाया जायेगा।

हस्ता./-
 मुख्य कार्यपालन अधिकारी
 स्वराशी चिकित्सा महाविद्यालय छिंदवाड़ा

इन्दिरा आई.टी.एफ. हॉस्पिटल प्रा. लि.

दिल्ली (पटेल नगर) : 9, साउथ पटेल नगर, पटेलनगर मेट्रो स्टेशन के पास, मेट्रो पिलर नं. 203 के सामने **दिल्ली (द्वारका) :** बिबा शोरूम के ऊपर, पालम एक्सटेंशन, रामपाल चौक, ब्रह्मा अपार्टमेन्ट्स के पास, सेक्टर-7, द्वारका **दिल्ली (रोहिणी) :** D-11/145, रोहिणी ईस्ट मेट्रो स्टेशन, पिलर नं. 391 के सामने, सेक्टर-8, रोहिणी, **दिल्ली (लाजपतनगर) :** ब्लॉक बी/24, मेट्रो पिलर नं.-9 के सामने, बंधन बैंक के पास, लाजपतनगर, **फरीदाबाद (रियर पोर्शन) SCO -13, सेक्टर-16 मार्केट, मोती महल रेस्टोरेन्ट के पास, SRL Lab एवं बैंक लाइन के पीछे, फरीदाबाद गाजियाबाद : विश्वकर्मा कॉम्प्लेक्स, मेट्रो पिलर नं. 191 के पास, यूनियन बैंक के ऊपर, सेक्टर-14, कौशाम्बी, गाजियाबाद, रोहतक : राज कॉम्प्लेक्स, राज मोटर्स के पास, लिबर्टी सिनेमा के सामने, डी-पार्क दिल्ली रोड, रोहतक हेल्पलाइन: 07665009964/65, ई-मेल : help@indralvf.in; वेबसाइट : www.indralvf.com**

40 Centres PAN India Treatment protocol as per individual need Patient friendly treatment options

दोरी दवाओं की प्रयोग अतिशय सावधानी से करना चाहिए। भ्रूण जिन परीक्षण करवाने जखम अमरुत 7 थक कार्य इमारत नहीं किया जात है

MINDA INDUSTRIES LTD.

REGD. OFFICE: B-64/1, WAZIRPUR INDUSTRIAL AREA,
 DELHI-110052 Ph: 011-27374444, 0124-2290427 Fax: 0124-2290676
 CIN: L74899DL1992PLC050333
 E-mail: sjain@mindagroup.com | Web: www.unominda.com



EXTRACTS OF THE AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH, 2018

Standalone				PARTICULARS	Consolidated			
₹ In Cr		₹ In Cr			₹ In Cr		₹ In Cr	
3 Months Ended	Year Ended	3 Months Ended	Year Ended		3 Months Ended	Year Ended	3 Months Ended	Year Ended
31-03-2018	31-03-2017	31-03-2018	31-03-2017					
Audited	Audited	Audited	Audited					
504.63	439.30	1903.80	1804.95	1. Total income from Operations	1,370.88	964.13	4548.29	3665.36
47.13	23.80	170.11	118.26	2. Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extra-Ordinary items)	124.21	74.74	390.31	231.62
47.13	23.80	175.60	118.26	3. Net Profit/(Loss) for the period before Tax (after Exceptional and/or Extra-Ordinary items)	162.45	74.74	428.55	231.62
36.25	20.58	135.83	93.96	4. Net Profit/(Loss) for the period after tax (after Exceptional and/or Extra-Ordinary items)	139.95	62.91	330.86	185.15
37.54	19.47	136.43	93.10	5. Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after tax) and other Comprehensive Income (after tax)	146.27	56.73	336.17	182.00
17.41	15.87	17.41	15.87	6. Equity Share Capital (Face Value Rs. 2 per share)	17.41	15.87	17.41	15.87
-	-	952.49	512.45	7. Reserves (excluding Revaluation Reserve as shown in the Audited Balance Sheet of Previous Year)	-	-	1374.28	743.58
4.19	2.59	15.72	11.83	8. Earnings Per Share (face value of Rs. 2 each) for continuing and discontinuing operations)				
4.18	2.53	15.67	11.77	a) Basic (in Rs.)	15.67	7.10	35.89	20.81
				b) Diluted (in Rs.)	15.62	7.01	35.78	20.72

32% NET REVENUE

73% PBT

88% PAT

73% EPS

Notes:-

- The consolidated and standalone financial results for the quarter and year ended on 31 March 2018 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 22 May 2018.
- The Board of Directors have recommended final dividend of Rs. 1.60 per share on the face value of Rs. 2 per share i.e. 80% to the equity shareholders for the Financial Year ended on 31 March, 2018, subject to approval by the shareholders at the Annual General Meeting. The interim dividend of Rs. 1.20 per share on the face value of Rs. 2 each i.e. 60% was paid to the equity shareholders, during the quarter ended on 31 March, 2018, therefore, the total dividend for the financial year ended on 31 March, 2018, aggregates to Rs. 2.80 per equity share of Rs. 2 each i.e. 140%.
- The above is an extract of the detailed format of the financial results of the company for the quarter and year ended on 31 March 2018 filed with stock exchanges pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of both these results (standalone and consolidated) are available on the stock exchange website(s) NSE website (www.nseindia.com), BSE website (www.bseindia.com) and on Company's website (www.unominda.com).

Place: Gurugram (Haryana)
 Date : 22 May, 2018

For and on behalf of the Board of
Minda Industries Limited
 (Nirmal K. Minda)
 Chairman & Managing Director

Consolidated Year on Year



"Minda Industries Limited is a flagship company of UNO MINDA Group. The Group is a Tier 1 Auto Component Supplier to all leading OEMs in India and across the Globe. It manufactures Automotive Switches, Lamps, Batteries, Horns, CNG/LPG Kits, Fuel Caps, Electronic Components, Alloy Wheels, Die Casting and Blow Moulding Components."

नवभारत दृष्टि 23-05-2018

New Delhi: Companies marketing medicines in India will soon be as liable as the manufacturers for any violations of drug regulations that could lead to spurious or substandard medicines. The move is expected to check lapses in quality of medicines consumed by patients in the country, according to persons aware of the development.

The Drugs Technical Advisory Board (DTAB) last week approved a proposal to amend the Drugs & Cosmetics Act to make pharmaceutical marketing firms liable for any contraventions of the regulations, a senior government official told ET on condition of anonymity.

This would allow the country's drug regulator to penalise firms marketing medicines in cases where the medicines are found to have violated the



regulations, the official said. This includes punishment like 3-5 years imprisonment for medicines flagged by regulators as not of standard quality or life imprisonment in cases where they are found spurious, the official added.

DTAB's approval would allow the health ministry to amend the regulations, making them applicable to companies listed as marketers on the

according to the official.

"Many a times, big pharmaceutical companies get their medicines manufactured by smaller companies. Today, if something (a violation) happens (to the quality of the product), only the manufacturer can be held responsible," said the official. "Now, legal action will be taken against both (the manufacturer and marketing company)."

The amendments are expected to make these companies liable for substandard and spurious samples of medicines marketed in the country as well as violations of any labelling norms, the official said.

"This will improve quality of medicines sold here because it will encourage the marketing companies to directly monitor their quality (before selling to patients)," the official added.

"A company which is getting (drugs) manufactured by a third party has to

product. Today, the law puts all the responsibility only on the manufacturer," said DG Shah, secretary general of the Indian Pharmaceutical Alliance, a lobby group for large domestic pharma companies in the country.

"If, from the outset, the legislation is clear and the responsibilities are defined, then marketing companies would take precautions to ensure facilities are as per GMP (Good Manufacturing Practices) standards and that manufacturing processes are followed as required," he said.

At the same time, some industry executives feel this development would be detrimental to pharmaceutical firms marketing products manufactured by third parties as it would make them liable for errors that they have not committed.

"It would be unfair for marketing companies. They are not in a position to vouch for the manufacturer," said an executive requesting anonymity.

MINDA INDUSTRIES LTD.

REGD. OFFICE: B-64/1, WAZIRPUR INDUSTRIAL AREA,
DELHI-110052 Ph: 011-27374444, 0124-2290427 Fax: 0124-2290676
CIN: L74899DL1992PLC050333
E-mail: sjain@mindagroup.com | Web: www.unominda.com



EXTRACTS OF THE AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH, 2018

Standalone				PARTICULARS	Consolidated			
3 Months Ended		Year Ended			3 Months Ended		Year Ended	
31-03-2018	31-03-2017	31-03-2018	31-03-2017		31-03-2018	31-03-2017	31-03-2018	31-03-2017
Audited	Audited	Audited	Audited		Audited	Audited	Audited	Audited
504.63	439.30	1903.80	1804.95	1. Total income from Operations	1,370.88	964.13	4548.29	3665.36
47.13	23.80	170.11	118.26	2. Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extra-Ordinary items)	124.21	74.74	390.31	231.62
47.13	23.80	175.60	118.26	3. Net Profit/(Loss) for the period before Tax (after Exceptional and/or Extra-Ordinary items)	162.45	74.74	428.55	231.62
36.25	20.58	135.83	93.96	4. Net Profit/(Loss) for the period after tax (after Exceptional and/or Extra-Ordinary items)	139.95	62.91	330.86	185.15
37.54	19.47	136.43	93.10	5. Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after tax) and other Comprehensive Income (after tax)	146.27	56.73	336.17	182.00
17.41	15.87	17.41	15.87	6. Equity Share Capital (Face Value Rs. 2 per share)	17.41	15.87	17.41	15.87
-	-	952.49	512.45	7. Reserves (excluding Revaluation Reserve as shown in the Audited Balance Sheet of Previous Year)	-	-	1374.28	743.58
4.19	2.59	15.72	11.83	8. Earnings Per Share (face value of Rs. 2 each) for continuing and discontinuing operations)				
4.18	2.53	15.67	11.77	a) Basic (in Rs.)	15.67	7.10	35.89	20.81
				b) Diluted (in Rs.)	15.62	7.01	35.78	20.72

Notes:

- The consolidated and standalone financial results for the quarter and year ended on 31 March 2018 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 22 May 2018.
- The Board of Directors have recommended final dividend of Rs. 1.60 per share on the face value of Rs. 2 per share i.e. 80% to the equity shareholders for the Financial Year ended on 31 March, 2018, subject to approval by the shareholders at the Annual General Meeting. The interim dividend of Rs. 1.20 per share on the face value of Rs. 2 each i.e. 60% was paid to the equity shareholders, during the quarter ended on 31 March, 2018, therefore, the total dividend for the financial year ended on 31 March, 2018, aggregates to Rs. 2.80 per equity share of Rs. 2 each i.e. 140%.
- The above is an extract of the detailed format of the financial results of the company for the quarter and year ended on 31 March 2018 filed with stock exchanges pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of both these results (standalone and consolidated) are available on the stock exchange website(s) NSE website (www.nseindia.com), BSE website (www.bseindia.com) and on Company's website (www.unominda.com).

Place: Gurugram (Haryana)
Date : 22 May, 2018

For and on behalf of the Board of
Minda Industries Limited
(Nirmal K. Minda)
Chairman & Managing Director

32%
NET REVENUE

73%
PBT

88%
PAT

73%
EPS

Consolidated Year on Year



Minda Industries Limited is a flagship company of UNO MINDA Group. The Group is a Tier 1 Auto Component Supplier to all leading OEMs in India and across the Globe. It manufactures Automotive Switches, Lamps, Batteries, Horns, CNG/LPG Kits, Fuel Caps, Electronic Components, Alloy Wheels, Die Casting and Blow Moulding Components.